Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Kolkata, West Bengal, India.
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Kolkata, West Bengal, India.
Pharmacol Biochem Behav. 2024 Oct;243:173828. doi: 10.1016/j.pbb.2024.173828. Epub 2024 Jul 18.
Cannabinoids, notably cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), have emerged as promising candidates for anxiety disorder treatment, supported by both preclinical and clinical evidence. CBD exhibits notable anxiolytic effects with a favourable safety profile, though concerns regarding mild side effects and drug interactions remain. Conversely, THC, the primary psychoactive compound, presents a range of side effects, underscoring the importance of careful dosage management and individualized treatment strategies. So far there are no FDA approved cannabinoid medications for anxiety. The review highlights challenges in cannabinoid research, including dosage variability, variable preclinical data, and limited long-term data. Despite these limitations, cannabinoids represent a promising avenue for anxiety management, with the potential for further optimization in formulation, dosing protocols, and consideration of interactions with conventional therapies. Addressing these challenges could pave the way for novel and personalized approaches to treating anxiety disorders using cannabinoid-based therapies.
大麻素，特别是大麻二酚（CBD）和Δ9-四氢大麻酚（THC），已成为治疗焦虑症的有前途的候选药物，这得到了临床前和临床证据的支持。CBD 具有显著的抗焦虑作用，且安全性良好，尽管仍存在对轻微副作用和药物相互作用的担忧。相比之下，THC 是主要的精神活性化合物，具有一系列副作用，突出了谨慎剂量管理和个体化治疗策略的重要性。迄今为止，还没有获得 FDA 批准的用于治疗焦虑症的大麻素药物。该综述强调了大麻素研究中的挑战，包括剂量变异性、临床前数据的可变性以及有限的长期数据。尽管存在这些局限性，但大麻素代表了一种有前途的焦虑症管理途径，有可能在配方、剂量方案方面进一步优化，并考虑与传统疗法的相互作用。解决这些挑战可能为使用大麻素为基础的治疗焦虑症的新型和个性化方法铺平道路。
